BT-TPO-AFL) grades of Recombinant Human Thrombopoietin/TPO as measured in a cell proliferation assay using MO7e human megakaryocytic leukemic cells (orange and green, respectively)." class="big_lightbox">

BT-TPO-AFL) grades of Recombinant Human Thrombopoietin/TPO as measured in a cell proliferation assay using MO7e human megakaryocytic leukemic cells (orange and green, respectively)." class="big_thumb" />
BT-SCF-GMP, 100 ng/mL), TPO (BT-TPO-GMP, 100 ng/mL), FLT-3L (
BT-FT3L-GMP, 100 ng/mL), and SR1 (Catalog #
7086, 1 µM). After 7 days, fold expansion was calculated from total viable cell counts. Cell viability on Day 7 was greater than 95% for all conditions. Frequency (%) CD34+ cells was analyzed by flow cytometry on Day 0 and Day 7 with an anti-human CD34 monoclonal antibody (Catalog #
MAB7227). CD34+ cell expansion was calculated by multiplying total nucleated cell (TNC) fold expansion by the CD34+ percentage. The average fold expansion of n=3 technical replicates is shown." class="big_lightbox">

BT-SCF-GMP, 100 ng/mL), TPO (BT-TPO-GMP, 100 ng/mL), FLT-3L (
BT-FT3L-GMP, 100 ng/mL), and SR1 (Catalog #
7086, 1 µM). After 7 days, fold expansion was calculated from total viable cell counts. Cell viability on Day 7 was greater than 95% for all conditions. Frequency (%) CD34+ cells was analyzed by flow cytometry on Day 0 and Day 7 with an anti-human CD34 monoclonal antibody (Catalog #
MAB7227). CD34+ cell expansion was calculated by multiplying total nucleated cell (TNC) fold expansion by the CD34+ percentage. The average fold expansion of n=3 technical replicates is shown." class="big_thumb" />
BT-SCF-GMP, 100 ng/mL), TPO (Catalog # BT-TPO-GMP, 100 ng/mL), FLT-3L (Catalog #
BT-FT3L-GMP, 100 ng/mL), and SR1 (Catalog #
7086, 1 µM). After 7 days, fold expansion was calculated from total viable cell counts. Cell viability on Day 7 was greater than 90% for all conditions. Frequency (%) CD34+ cells was analyzed by flow cytometry on Day 0 and Day 7 with an anti-human CD34 monoclonal antibody (Catalog #
MAB7227). CD34+ cell expansion was calculated by multiplying total nucleated cell (TNC) fold expansion by the CD34+ percentage. The average fold expansion of n=4 technical replicates is shown." class="big_lightbox">

BT-SCF-GMP, 100 ng/mL), TPO (Catalog # BT-TPO-GMP, 100 ng/mL), FLT-3L (Catalog #
BT-FT3L-GMP, 100 ng/mL), and SR1 (Catalog #
7086, 1 µM). After 7 days, fold expansion was calculated from total viable cell counts. Cell viability on Day 7 was greater than 90% for all conditions. Frequency (%) CD34+ cells was analyzed by flow cytometry on Day 0 and Day 7 with an anti-human CD34 monoclonal antibody (Catalog #
MAB7227). CD34+ cell expansion was calculated by multiplying total nucleated cell (TNC) fold expansion by the CD34+ percentage. The average fold expansion of n=4 technical replicates is shown." class="big_thumb" />